Navigation Links
ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410

FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second mechanism of action which prevents the entry of HIV into target cells and significantly raises the potential genetic barrier to resistance with IQP-0410 therapy. Preclinical pharmacokinetic and toxicology studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against multi-drug resistant virus strains obtained from patients failing long courses of therapy with currently approved RT and protease inhibitors. The compound is well suited for use as a component of primary HAART regimens as well as a salvage therapy option. Preclinical studies have also demonstrated the ability of the compound to be used in combination with all other approved HIV drugs.

"The submission of this IND represents a critical milestone in the therapeutic development of the pyrimidinedione class of molecules as potential new HIV drugs and an important success in the strategic drug development initiatives between ImQuest and Samjin Pharmaceutical Co. Ltd of Seoul, KOREA," said Dr. Robert W. Buckheit, Jr., Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "We believe that IQP-0410 will be a new and novel addition to the armamentarium of HIV drugs available and provide HIV-infected individuals with a safe and effective alternative to current therapies."

ImQuest and Samjin have continued their strategic efforts to develop additional pyrimidinediones as next generation NNRTIs with an enhanced genetic barrier to resistance as well as efforts to develop a topical microbicide to prevent the sexual transmission of HIV. Additionally, ImQuest's development of Samjin's piperazine anti-tumor agents for the treatment of both solid and hematopoietic tumors has progressed to IND-enabling toxicology evaluations. These products are expected to enter human clinical trials in late 2009 and 2010.

ImQuest Life Sciences ( in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences ( is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry. Established in 1968, Samjin Pharmaceutical Co. ( is dedicated to the manufacture, distribution and marketing of novel pharmaceuticals resulting in numerous international patents covering antiviral, anticancer, and metabolic candidate compounds. The company has recently expanded their scope to include stem cell research and the active pursuit of diabetic treatments.

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
4. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
7. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
8. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
10. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse and ... findings on the website. Click here to read the details now. ... were treated with chemotherapy followed by EPP surgery. Among the 106 patients who relapsed, ...
(Date:11/27/2015)... ... 27, 2015 , ... The print component of “Supporting Our ... Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies ... a vast social media strategy and across a network of top news sites ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical ... of CAAHEP accredited colleges, as only one of twelve colleges and universities in the ...
Breaking Medicine News(10 mins):